Update on treatment of hereditary angioedema

Asian Pacific Journal of Allergy and Immunology

Volumn 30, Issue 2, 2012, Pages 89-98

  Buyantseva, Larisa V ^a   Sardana, Niti ^b   Craig, Timothy J ^c  

^a Harrisburg Hospital   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bradykinin; C1 esterase inhibitor; C1 inhibitor; Ecallantide; Hereditary angioedema treatment; Icatibant; Prophylaxis; Recombinant Cinhibitor

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; METHYLTESTOSTERONE; OXANDROLONE; STANOZOLOL; UNCLASSIFIED DRUG;

ACNE; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BURNING SENSATION; CLINICAL ASSESSMENT; DRUG APPROVAL; DRUG INDICATION; DYSLIPIDEMIA; ERYTHEMA; FATIGUE; GENERAL PRACTITIONER; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INFECTION RISK; INJECTION SITE EDEMA; LIBIDO DISORDER; LIVER NECROSIS; LIVER TUMOR; MENSTRUAL IRREGULARITY; NAUSEA; PEER REVIEW; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; SIDE EFFECT; SKIN IRRITATION; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VIRILIZATION; WEIGHT GAIN;

ANDROGENS; ANGIOEDEMAS, HEREDITARY; BRADYKININ; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPLEMENT C1 INHIBITOR PROTEIN; DATABASES, BIBLIOGRAPHIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; NARCOTICS; PEPTIDES; PLACEBOS; PLASMA; RECOMBINANT PROTEINS;

EID: 84863479695     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Craig T, Riedl M, Dykewicz MS, Gower RG, Baker J, Edelman FJ, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol. 2009;102:366-72.
2. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy. 2011;66:76-84.
3. Ferraro MF, Moreno AS, Castelli EC, Donadi EA, Palma MS, Arcuri HA, et al. A single nucleotide deletion at the C1 inhibitor gene as the cause of hereditary angioedema: insights from a Brazilian family. Allergy. 2011;66:1384-90.
4. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol. 2011;141;31-5.
5. Mendelian Inheritance in Man. A Catalog of Human Genes and Genetic Disorders [database on the Internet]. Baltimore: Johns Hopkins University Press. 1998. Available from: http://omim.org/.
6. Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis. 2009;20:325-32.
7. Nagy N, Greaves MW, Tanaka A, McGrath JA, Grattan CE. Recurrent European missense mutation in the F12 gene in a British family with type III hereditary angioedema. J Dermatol Sci. 2009;56:62-4.
8. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol. 2006;154:542-5.
9. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359:1027-36.
10. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407-14.
11. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267-74.
12. Prematta MJ, Kemp JG, Gibbs JG, Mende C, Rhoads C, Craig TJ. Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc. 2009;30:506-11.
13. Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol. 2010;104:211-4.
14. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163:1229-35.
15. Ben Maamer A, Zaafouri H, Haoues N, Cherif A. Acute pancreatitis due to hereditary angioedema. Tunis Med. 2011;89:579-80.
16. Dhairyawan R, Harrison R, Buckland M, Hourihan M. Hereditary angioedema: an unusual cause of genital swelling presenting to a genitourinary medicine clinic. Int J STD AIDS. 2011;22:356-7.
17. Bowen T. Hereditary angioedema: beyond international consensus-circa December 2010-The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy Asthma Clin Immunol. 2011;7:1.
18. Tourangeau LM, Zuraw BL. The new era of C1-esterase inhibitor deficiency therapy. Curr Allergy Asthma Rep. 2011;11:345-51.
19. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol. 2011;106:316-22. e4.
20. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6:24.
21. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, von Hentig N, Klingebiel T, Kreuz W. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion. 2010;50:354-60.
22. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124:801-8.
23. Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152:44-9.
24. Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc. 2008;29:225-31.
25. Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy. 2011;66:1604-11.
26. Zuraw BL. HAE therapies: past present and future. Allergy Asthma Clin Immunol. 2010;6:23.
27. Choi G, Soeters MR, Farkas H, Varga L, Obtulowicz K, Bilo B, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47:1028-32.
28. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821-7. e14.
29. Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011;7:143-53.
30. Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy. 2012;67:123-30.
31. Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann Allergy Asthma Immunol. 2008;100:S41-6.
32. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120:416-22.
33. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523-31.
34. Levy R, McNeil D, Li H, Hsu FL, Horn P, Roberts J. Results of a 2-stage, phase 2 pivotal trial EDEMA3: a study of subcutaneous DX-88 (Ecallantide), a plasma kallikrein Inhibitor, in patients with Hereditary Andioedema (HAE). J Allergy Clin Immunol. 2008:S231.
35. Banta E, Horn P, Craig TJ. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: Results from the EDEMA clinical trials. Allergy Asthma Proc. 2011;32:319-24.
36. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532-41.
37. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010;9:189-90.
38. Greve J, Hoffmann TK, Schuler P, Lang S, Chaker A, Bas M. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema. Int J Dermatol. 2011;50:1294-5.
39. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007;98:383-8.
40. Dagen C, Craig TJ. Treatment of Hereditary Angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol. 2010;6:11.
41. Farkas H, Varga L, Szeplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120:e713-22.
42. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513-22.
43. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011;66:192-6.
44. Zuraw BL. Novel therapies for hereditary angioedema. Immunol Allergy Clin North Am. 2006;26:691-708.
45. Toscani M, Riedl M. Meeting the challenges and burdens associated with hereditary angioedema. Manag Care. 2011;20:44-51.
46. Bhasin A, Lunn M, Fisher-Olivieri K, Craig ET, editors. Cost of treating hereditary angioedema with newly available medications in five different settings. 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology 2011 Nov 3-8, 2011; Boston, MA.
47. Kalaria S, Baman N, Craig TJ, editors. Hereditary angioedema treatments and their risk of thrombotic events. 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology; 2011; Boston, MA.
48. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol. 2008;121:272-80.
49. Davis B, Bernstein JA. Conestat alfa for the treatment of angioedema attacks. Ther Clin Risk Manag. 2011;7:265-73.
50. Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Heller C, Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion. 2012;52:100-7.